The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.

On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China, from drug development and diagnostics to Hospital management, will benefit from the AI revolution.

wallstreetcnFeb 27 03:39 ET

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

The era of large models in medicine! AI empowers the Industry to press the "accelerator", while the industry still hopes for revolutionary technology to emerge | Medicine Bottoming Series ④

① AI, with its powerful data summarization capabilities, is driving further innovation in the Medical and pharmaceutical fields; ② however, pharmaceutical companies still feel troubled about how to leverage AI in research and development; ③ industry insiders believe that the limitations of technology and the inviolability of ethical and legal responsibilities objectively prevent AI from having the capability to be a responsible entity.

cls.cnFeb 26 02:44 ET

Are Innovative Drugs receiving a New Year's bonus at the start of the year? Support from medical insurance policies may come in multiple ways, and listed companies express that they will "seize the opportunity."

① Two major consultation drafts focus on the pricing and payment of Innovative Drugs, proposing multiple specific innovative mechanisms, further igniting enthusiasm in the Innovative Drugs Industry; ② Industry experts believe that the Class B medical insurance catalog serves as a shot in the arm, but attention should be paid to expanding its Fund pool and further measures to guide insured enthusiasm; ③ Many listed companies have noticed this dynamic and stated they will "closely monitor, actively cooperate in the future, and seize opportunities."

cls.cnFeb 21 04:16 ET

It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.

① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.

cls.cnFeb 20 18:46 ET

Pharmaceutical companies are racing in AI! The leading CRO has acquired an AI company in the oncology field, with another player entering the Sector of large models.

① PHARMARON officially announced yesterday that it has acquired the AI company Haixin Zhihui, which specializes in patient management in the field of oncology, to improve the efficiency of new drug development; ② Many CRO companies have already begun to invest in AI, and investors are bullish on the future potential of this Business; ③ In the past 18 trading days, the CRO Concept has seen a continuous surge.

cls.cnFeb 20 03:15 ET